Interferon State of the Science and Strategic Opportunities

At the end of 2004 the world market for Interferon was valued at $5.9 billion, a growth of 13% over 2003. The market has been growing at an average annual growth rate of 17% over the previous 5 years.

The interferon market is application driven and clearly demarcated along the lines of the type of the interferon molecule. At 60% share, interferon Beta accounts for the main bulk of the market followed by interferon Alfa at 37% market share.

Interferon alfa therapy is used as a frontline treatment for a number of indications including the treatment of malignant melanoma, hairy cell leukemia, chronic hepatitis B, chronic hepatitis C, condylomata acuminata, follicular (non-Hodgkin's) lymphoma, and AIDS-related Kaposi's sarcoma

Worldwide, 350 million people are thought to be chronically infected with HBV, a highly infectious pathogen that is responsible for an estimated 1 million deaths annually and more than 170 million people are infected with HCV with 3 to 4 million new cases occurring each year.

The main indication for interferon beta is Multiple Sclerosis (MS), a disease of the central nervous system (CNS), affecting over 400,000 people in the US and 1.2 million in the developed world.

Interferon - Current Market Dynamics & Future Outlook is a timely strategic consulting report from ASInsights assessing both the technology status and the competitive landscape of Interferon Alfa, Beta & Gamma and their application areas.

The report profiles leading products and companies and offer revenue forecasts to the year 2010.

Report Code: ASI0505-2

Date Published: May 2005

Number of Pages: 30

Report Price: US$480 - PDF file by email, US$960 - Site License
View Table of Contents...

Price
PDF Format $480.00
Site Licence - $960.00